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aricella  is  one  of  the  most  common  infectious  diseases,  with
 worldwide  distribution.  According  to  a  WHO  position  paper,
he  global  annual  disease  burden  of  varicella  is  estimated  to
e  140  million  cases.1 Despite  the  public  perception  of  vari-
ella  infection  as  a  harmless  childhood  afﬂiction,  it  can  be
 very  serious  disease.  As  Martino  Mota  &  Carvalho-Costa
ighlight  in  ‘‘Varicella  zoster  virus  related  deaths  and  hos-
italizations  in  Brazil  before  the  introduction  of  universal
accination  with  the  tetraviral  vaccine,’’  varicella  can  cause
eath  or  can  lead  to  potentially  serious  complications,  which
equire  hospitalization  and  eventually  long-term  sequelae.2
Varicella-related  hospitalization  rates  differ  widely
orldwide.  Varicella  may  potentially  afﬂict  any  organ;
ematological,  neurological,  respiratory,  cutaneous,
epatic,  gastrointestinal,  urinary,  and  bone  complications
re  the  most  frequently  reported.3
The  incidence  of  varicella  complications  differs  among
cientiﬁc  reports.  For  example,  the  pooled  prevalence
f  neurological  complications  resulting  from  a  systematic
eview  of  the  literature  identiﬁes  the  likelihood  of  pediatric
eurological  complications  in  the  range  of  13.9--20.4%.4 Nev-
rtheless,  in  some  reports  the  rate  of  varicella  neurological
 Please cite this article as: Bozzola E, Bozzola M. Varicella
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 See paper by Martino Mota & Carvalho-Costa in pages 361--6.
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icense (http://creativecommons.org/licenses/by-nc-nd/4.0/).omplications  is  lower  than  the  incidence  reported  in  the
iterature,  while  other  complications,  such  as  skin  infec-
ions,  are  the  most  frequently  detected.5,6 In  other  reports,
he  rate  of  both  neurological  and  cutaneous  complications
s  low,  while  other  complications  are  frequently  detected,
uch  as  respiratory  ones.7 This  ﬁnding  may  be  related  to
ifferences  in  the  sociodemographic  structure  of  the  popula-
ion  or  to  a  broader  availability  of  outpatient  skin-infection
reatments  or  to  different  hospitalization  policies.
Patients  with  a  history  of  underlying  malignancy,  steroid
se  or  immunosuppressive  therapy,  HIV  infection,  or  solid
rgan  transplantation  are  susceptible  to  disseminated  vari-
ella  due  to  impaired  cellular  immunity.  Immunosuppressed
osts  who  develop  varicella  experience  severe  morbidity  and
igher  mortality  rates  more  frequently  than  normal  hosts.
or  example,  patients  with  rheumatologic  or  gastroentero-
ogical  diseases  treated  with  tumor  necrosis  factor  (TNF)
ntagonists  remain  at  selectively  increased  risk  for  more
evere  primary  varicella  infections  compared  with  the  gen-
ral  population.8,9
In  the  report  by  Martino  Mota  &  Carvalho-Costa,  the
ajority  of  deaths  and  of  varicella-associated  complications
ccurred  in  children  aged  1--4  years.  Similarly,  in  the  litera-
ure,  the  highest  frequency  of  varicella  complications  occurs
n  those  younger  than  5  years.3,6,10
Varicella  may  also  be  very  serious  in  the  elderly,  as  it
ay  be  fatal  or  lead  to  prolonged  hospitalization.8 Pregnant
omen  are  a  particular  concern.  If  a  woman  develops  vari-
ella  at  an  early  gestational  age,  the  child  may  experience
ongenital  varicella  syndrome;  if  she  gets  ill  at  the  end  of
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pregnancy,  the  neonate  may  present  varicella.  Both  condi-
tions  are  very  serious  for  the  newborn.11
Vaccination  may  prevent  varicella  infection  and  its
complications.  A  varicella  vaccine,  based  on  the  attenuated
live  varicella  zoster  virus  Oka  strain,  was  developed  in  Japan
in  the  mid-1970s.  Since  then,  different  formulations  of  vari-
cella  vaccines  had  been  proposed.  All  of  them  contain  live
attenuated  varicella  zoster  virus,  and  all,  except  the  vaccine
licensed  in  South  Korea,  are  based  on  the  Oka  strain  iso-
lated  in  Japan.  Currently,  varicella  vaccines  are  licensed  as
a  monovalent  or  as  a  combination  measles,  mumps,  rubella,
varicella  vaccine  (MMRV).  MMRV  vaccines  are  currently  used
on  the  basis  of  a  comparable  immunogenicity  and  overall
safety  proﬁle  compared  with  simultaneous  administration
of  MMR  and  varicella  vaccines.12 Moreover,  as  it  requires
a  single  injection,  MMRV  vaccine  is  expected  to  offer  sev-
eral  beneﬁts:  facilitation  of  universal  immunization  against
these  four  diseases,  increased  compliance  with  immuniza-
tion,  and  reduced  healthcare  costs.
In  a  study  focusing  on  post-licensure  varicella  vaccine
effectiveness  among  healthy  children,  the  authors  ana-
lyzed  systematic  reviews  and  meta-analyses  of  the  MEDLINE,
Embase,  Cochrane  Library,  and  CINAHL  databases  for  reports
published  during  1995--2014.  They  concluded  that  one  dose
of  varicella  vaccine  was  moderately  effective  in  preventing
varicella  diseases  (81%)  and  highly  effective  in  preventing
moderate  and  severe  manifestations  of  varicella  (98%).  The
authors  concluded  that  a  second  dose  adds  increased  pro-
tection  against  varicella  (92%).13
Nevertheless,  vaccination  policies  differ  from  country
to  country.  In  some,  such  as  the  United  States  and  Aus-
tralia,  universal  immunization  was  introduced  many  years
ago.  Such  mass  vaccination  progressively  led  to  a  substantial
decrease  in  disease  burden.14
With  regard  to  Europe,  there  is  no  consensus  on  vari-
cella  immunization  policy.  Consequently,  some  countries,
such  as  Germany  and  Greece,  have  national  childhood
immunization  programs.  Others  adopt  heterogeneous  or  no
ofﬁcial  recommendations.15 In  Italy,  since  its  commercial-
ization,  some  regions  have  offered  universal  vaccination  in
childhood,  with  a  consequently  reduced  incidence  of  the
disease.16
In  other  regions,  varicella  vaccine  coverage  strongly
depends  on  the  acceptance  of  the  vaccination  by  parents
and  on  pediatricians’  recommendations.  Pediatricians  may
underestimate  both  the  potential  risk  of  the  disease  and  the
economic  burden  for  the  community.  Parents  may  consider
the  potential  proﬁt  for  the  community  as  less  important
than  the  individual  risk  to  their  child  from  potential  uninten-
tional  side  effects  of  vaccination.  Vaccine-declining  parents
believe  that  the  vaccine  is  unsafe  and  ineffective,  as  well
as  that  the  disease  it  is  given  to  prevent  is  mild  and
harmless.  Moreover,  in  some  cases,  parents  mistrust  health
professionals,  the  government,  and  ofﬁcially-endorsed  vac-
cine  research  but  trust  media  and  non-ofﬁcial  information
sources,  which  discourage  immunization  policies.  In  most
cases,  families  must  pay  the  cost  of  vaccination  if  they  wish
their  children  to  be  immunized.  Hence,  high  coverage  levels
may  be  difﬁcult  to  achieve.
Decisions  on  vaccine  funding  are  based  on  many  consid-
erations,  including  the  likely  cost-effectiveness  of  different
immunization  strategies.  In  European  countries  that  have329
mplemented  vaccination  on  a  national  level,  mass  immu-
ization  has  resulted  in  both  decreased  disease  incidence
nd  reduced  hospitalization  rates.  Moreover,  data  have  also
evealed  beneﬁts  for  unvaccinated  groups,  such  as  infants
ounger  than  one  year.17 In  fact,  a  high  immunization  rate
ontributes  in  preventing  the  spread  of  varicella  infection,
 concept  known  as  herd  immunity.  Herd  immunity  provides
rotection  to  those  who  are  at  highest  risk  for  severe  vari-
ella  infection,  including  pregnant  women,  infants,  persons
ith  human  immunodeﬁciency  virus  and  other  immuno-
eﬁciency  disorders,  those  receiving  chemotherapy,  and
atients  treated  with  high-dose  corticosteroids.  This  is  a
ery  important  goal,  as  many  hospital  admissions  occur  in
nfants  too  young  to  be  vaccinated.3 Therefore,  as  rates
f  vaccine  refusal  increase,  herd  immunity  wanes,  and  cer-
ain  vulnerable  populations  will  be  at  higher  risk  for  severe
aricella  infection.
Further,  an  economic  analysis  of  a  universal  vaccination
rogram  indicates  that  it  would  likely  be  cost-saving  due  to
eduction  in  both  medical  costs  and  in  loss  of  parents’  work
ime.18 Finally,  countries  should  also  consider  vaccination
f  seronegative  health-care  workers,  especially  in  settings
here  the  risk  of  severe  varicella  is  high  (i.e.,  immunocom-
romised  patients,  premature  infants,  etc.).
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